Skip to content
News Radio KOTA
    • Sample Page
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Author: Entera Bio Ltd.

Posted Date:

June 22, 2026
  • Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

    Entera Bio Ltd.
    June 22, 2026
  • Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

    Entera Bio Ltd.
    June 16, 2026
  • ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

    Entera Bio Ltd.
    June 15, 2026
  • Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

    Entera Bio Ltd.
    May 28, 2026
  • Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

    Entera Bio Ltd.
    May 8, 2026
  • Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

    Entera Bio Ltd.
    April 14, 2026
  • Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

    Entera Bio Ltd.
    April 2, 2026